DONATE TODAY
To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

August 1, 2022

DISEASE EDUCATION: The End Brain Cancer Initiative (EBCI) this month is sharing with you information related to a very rare disease that only affects @ 1,500 people in the U.S. annually. This disease is known as PCNSL

PROSPECT Logo

PROSPECT is an open-label, Phase II study evaluating the efficacy, safety, and pharmacokinetics of an investigational oral medicine called Tirabrutinib (ONO-4059), a Bruton’s tyrosine kinase (BTK) inhibitor, in patients with primary central nervous system lymphoma (PCNSL).

The PROSPECT study is for patients diagnosed with PCNSL, a primary central nervous system lymphoma which is a type of cancer originating from immune cells known as lymphocytes that develop in the brain and/or spinal cord (central nervous system).

There are currently no therapeutic products/treatments specifically approved for the treatment of PCNSL in the U.S., therefore, a new treatment option is needed for patients diagnosed with PCNSL and relapsed PCNSL. EBCI would like to thank ONO PHARMA USA, Inc. for investing in this disease area to help lead the U.S. in exploring effective treatment options for this disease.

Additional information can be found at www.EndBrainCancer.org at the PROSPECT TRIAL/ONO PHARMA USA web landing page as well as at https://www.prospectstudy.com, which also offers an online “pre-screener” for this trial.

Dr. Daniela Bota, the Study Principal Investigator (PI) may be contacted at 714-456-7214 or at dbota@hs.uci.edu for more information and to see if you are eligible to enroll into this clinical trial for the treatment of PCNSL. This study is currently recruiting 39 more patients in the U.S.

Photo of Dellann

Dellann Elliott Mydland
President & Board Chair

The EndBrainCancer Initiative | Chris Elliott Fund
Dellann@EndBrainCancer.org

EndBrainCancer.org

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
DONATE
corporate partners
upcoming events
resources
About us
envelopephonemap-markerpointer-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram